Navigation Links
United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
Date:3/21/2011

SILVER SPRING, Md., March 21, 2011 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

FREEDOM-C(2) is a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study of a sustained release oral formulation of treprostinil diethanolamine (UT-15C) in pulmonary arterial hypertension (PAH) patients receiving an endothelin receptor antagonist and/or a phosphodiesterase-5 inhibitor.

The FREEDOM-C(2) study randomized 313 patients, compared to a target enrollment of 300 patients.  The primary endpoint of the trial is change in six-minute walk distance at Week 16 in the treatment group compared to placebo.

"Completion of enrollment in FREEDOM-C(2) represents another significant milestone toward the planned filing of the UT-15C NDA," said Roger Jeffs, Ph.D., President and Chief Operating Officer of United Therapeutics. "This study, if successful, will support the use of UT-15C as add-on therapy to currently approved oral medications, and should significantly enhance early adoption and market uptake of UT-15C."

United Therapeutics expects to unblind and announce preliminary analysis of the FREEDOM-C(2) study results in September 2011.

About United Therapeutics Corporation

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations on th
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
2. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
3. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
4. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
5. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
6. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
7. Report Details How States Respond to Citizens United Decision
8. United Nations' World Population Day Calls Attention to Key Global Issues
9. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
10. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
11. Abt Bio-Pharma Solutions, Inc. Acquired by United BioSource Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
(Date:5/17/2013)... 17, 2013 Tooth decay is an epidemic ... signs of the disease. The World Health Organization says that ... of adults have cavities. What are the long-term effects of ... a strong connection between the oral bacterial imbalance and serious ... so rampant, yet it is also 100% preventable? Answer: there ...
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of Palm ... China about Appearance Medicine . Although Dr. Hart regularly ... trip to lecture in China, and quite a different experience ... to 12 and 7 million people respectively. Interest in cosmetic ... point in time. As Dr. Hart passed through the Fuzhou ...
(Date:5/16/2013)... May 16, 2013  HealthSparq, a trusted provider ... nation,s largest regional health plans, will debut a ... Plans (AHIP) Institute 2013 conference on June 13. ... showing how health insurance companies across the country ... and marketplace demands for increased healthcare transparency. ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3
... Inc. (OTC/BB: TBIO) today announced the following Webcast:What: ... Business Update Conference CallWhen: , Thursday, May 12, 2011 ... Live over the Internet -- Simply log on to ... 402-452-5400To access the call via telephone, call 800-895-0198 from ...
... Sciences, Inc. (NASDAQ: CALP ), a leading ... life sciences research for personalized medicine, will be hosting ... 17th and 18th.  This annual event brings together global ... the technologies and discoveries that are transforming the detection ...
... May 5, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the development and commercialization of products for central nervous ... the first quarter ended March 31, 2011. ... have made to date in 2011," said Mihael H. ...
Cached Biology Technology:Transgenomic to Hold First Quarter Financial Results Conference Call on May 12, 2011 2Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 3Vanda Pharmaceuticals Reports First Quarter 2011 Results 4Vanda Pharmaceuticals Reports First Quarter 2011 Results 5Vanda Pharmaceuticals Reports First Quarter 2011 Results 6Vanda Pharmaceuticals Reports First Quarter 2011 Results 7Vanda Pharmaceuticals Reports First Quarter 2011 Results 8
(Date:5/16/2013)... , May 16, 2013 Reportlinker.com ... is available in its catalogue: ... Opportunities, 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... old security practises such as photographs, passwords ... of biometric technologies in last few years. ...
(Date:5/15/2013)... In the largest clinical trial to date to examine ... carriers with diseases other than breast and ovarian cancer, ... against advanced pancreatic and prostate cancers. Results of the ... Medicine at the University of Pennsylvania and Sheba Medical ... the American Society of Clinical Oncology,s annual meeting in ...
(Date:5/15/2013)... frontier explorer and world-renowned filmmaker James Cameron has been ... Diego as the recipient of the 2013 Nierenberg Prize ... a presentation on his record-setting DEEPSEA CHALLENGE expedition and ... Friday, May 31, on the UC San Diego campus. ... probe the mysteries and promise of the deep sea ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2James Cameron to be publicly honored with Scripps Nierenberg Prize 2James Cameron to be publicly honored with Scripps Nierenberg Prize 3James Cameron to be publicly honored with Scripps Nierenberg Prize 4
... the latest issue of the journal Nature, scientists at ... of the National Institutes of Health (NIH) describe a ... lead to new ways of thinking about how to ... , Led by immunologist Ronald Germain, M.D., Ph.D., the ...
... A pig used for research at the University of ... will provide the first sequence of the swine genome ... $10 million grant from the U.S. Department of Agriculture ... , Lawrence B. Schook, a professor of animal sciences ...
... Scientists at The University of Texas at Austin have developed ... that surrounds bacteria and plays a role in infection and ... during the course of an infection, cloaking the bacteria from ... the sugars were too slow to catch these rapid changes. ...
Cached Biology News:Chemical guidance of T cells leads to immunologic memory and long-term immunity 2Chemical guidance of T cells leads to immunologic memory and long-term immunity 3Illinois pig to make history as source of first complete swine genome 2Scientists seek to unwrap the sweet mystery of the sugar coat on bacteria 2
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
... controls for monitoring Aldolase tests. 2 ... with targeted manufacturing values at 4 ... 3 IU/L. 30-day shelf life ... C. Level 1: 3 x 3 ...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Recombinant Mouse sTNF RII/TNFRSF1B...
Biology Products: